ARWR

ARWR reaches the end of its 15-session observation window with the canonical session-15 outcome still pending. The fresh after-market capture is $87.25, or -3.59% from the $90.50 reference, versus $89.24 at the prior regular close; the extended quote is $87.30, up 0.06% after hours. The original thesis linked the move to a public report about Arrowhead drug efficacy. The record shows repeated repair attempts, but light participation and weak follow-through left the thesis unconfirmed. Tracking now ends: this closure does not invent a session-15 return, and the pending canonical outcome remains an explicit limitation.

ARWR's tracked return is -2.65%, down 1.16 points since the previous public note, while the latest capture moved -1.1% on 0.26x volume and sat -0.75% from VWAP. The published thesis remains under pressure; a 16.38-point Healthcare advantage and the current structure remain relevant, but The weak capture keeps the repair question open rather than confirming a turn.

ARWR slipped to -1.49%, a 0.10-point retreat since the last public note, while the latest capture fell 0.45% on 0.05x volume and sat 0.76% below VWAP. Rising EMAs and an 18.55-point sector advantage keep the repair case alive, but thin activity and neutral flow leave follow-through unconfirmed.

ARWR's tracked return remains -1.39% while the latest capture gained 1.03% on 0.48x volume. Rising EMAs and a 17.96-point sector advantage keep the repair case alive, but neutral flow and light participation leave follow-through unconfirmed.

ARWR's tracked return was unchanged at -1.39%, while the latest capture rose 1.03% on 0.48x volume. Rising EMAs and a 17.96-point 20-session sector advantage keep the repair case intact, but neutral flow and below-average activity leave follow-through unconfirmed.

ARWR added 1.03% in the latest capture, but price remained 0.38% below VWAP on 0.48x participation with neutral flow. The rising EMA structure and 17.96-point sector advantage keep the repair thesis alive, while the absence of stronger demand leaves follow-through unconfirmed.

ARWR slipped 1.09 percentage points in tracked return to -2.10% while the latest capture added only 0.17% on 0.30x participation and closed 1.40% below VWAP. The rising EMA structure and 16.81-point sector advantage still support a repair reading, but neutral flow, thin dollar activity and the loss of intraday range leave follow-through unconfirmed.

ARWR's tracked return improved 1.39 points to -1.01% as the latest capture rose 1.27%, but participation was only 0.07x and price sat 0.58% below VWAP. The rising EMA structure and 18.24-point sector advantage keep the repair thesis in play; neutral flow leaves follow-through unconfirmed.

The latest capture added 0.78% on 0.39x participation while ARWR's tracked return held at -2.40%. The rising EMA stack and 14.83-point 20-session advantage over its sector keep the repair case alive, but neutral flow, RSI 70.92 and light demand still leave follow-through unconfirmed.

ARWR's tracked return slipped 0.27 percentage points to -2.13% as the latest capture gained 0.78% on 0.39x participation and held 0.22% above VWAP. The rising EMA stack and 14.83-point sector advantage keep the repair thesis alive, but neutral flow, high RSI and light demand still leave follow-through unconfirmed.

ARWR's tracked return improved 1.10 percentage points from the previous public note, while the latest capture rose 0.75% on 0.22x participation and held 0.31% above VWAP. Rising EMAs and a 15.10-point sector advantage keep the repair thesis alive, but thin demand, neutral flow and high RSI leave the move unconfirmed; the panel sees improvement in the tape, not a completed repair.

ARWR's tracked return is nearly unchanged at -3.15% after a flat latest capture on only 0.06x participation. Price remains 0.21% above VWAP with rising EMAs and a 14.69-point sector advantage, but thin demand and neutral flow leave the repair case open without confirming follow-through.

ARWR's tracked return remains at -3.15% as the latest capture rose 2.12% on 0.43x participation. Rising EMAs and an 11.72-point sector advantage keep the repair case open, but RSI 72.73, neutral flow and unavailable VWAP evidence leave the move unconfirmed.

ARWR's tracked return was nearly unchanged, easing 0.07 percentage points to -3.15% as the latest capture rose 2.12% on 0.42x participation. Rising EMAs and an 11.72-point sector advantage keep the repair case open, but elevated RSI, neutral flow and unavailable VWAP evidence leave the move unconfirmed.

ARWR recovered 2.08 percentage points in tracked return to -3.08% as the latest capture rose 1.69% on only 0.08x participation. Rising EMAs and an 11.75-point sector advantage support a repair attempt, but price remains 0.47% below VWAP and neutral flow leaves confirmation dependent on stronger demand.

ARWR's latest capture fell 1.24% on 0.46x participation, even as the rising EMA structure preserves a possible repair path. Neutral flow, only a 0.77-point sector edge and unavailable VWAP evidence leave stronger demand necessary for confirmation.

ARWR's tracked return fell 1.19 percentage points to -5.16%, while the current capture slipped 1.24% on 0.46x participation. Rising EMAs and a narrow 0.77-point sector edge keep the efficacy-linked repair case open, but neutral flow, distribution in the current close and no VWAP capture leave stronger demand necessary for confirmation.

ARWR's tracked return is unchanged at -3.97% while the latest capture fell 2.99% on 0.74x participation. Rising EMAs and a narrow 0.21-point sector edge keep the efficacy-linked repair case open, but neutral flow, RSI 70.51 and unavailable VWAP evidence leave stronger demand necessary for confirmation.

ARWR's tracked return slipped 1.35 points to -3.97% as the latest capture fell 2.99% on 0.74x participation. Rising EMAs and a slight 0.21-point sector edge keep the efficacy-linked repair case from failing outright, but neutral flow, RSI 70.51 and unavailable VWAP evidence mean stronger demand is still needed.

ARWR's tracked return slipped 1.35 percentage points to -3.97% as the latest capture fell 2.99% on 0.74x participation. The rising EMA structure and a narrow 0.21-point edge versus the sector keep the efficacy-linked repair case from failing outright, but neutral flow and RSI 70.51 make stronger demand necessary for confirmation.

ARWR's tracked return slipped 1.61 points as the latest capture fell 2.02% to $87.78, but price remained 0.53% above VWAP and the EMA structure stayed rising. Neutral accumulation, 0.13x participation and RSI 72.17 temper the efficacy-linked repair case; the move needs stronger demand to become confirmed continuation.

ARWR held its -1.01% tracked return as the latest capture climbed 4.16% to $89.59 on 0.91x participation. Rising EMAs and a 4.43-point sector-relative advantage support repair, while neutral flow, RSI 74.93 and no current VWAP reading keep the recovery unconfirmed.

ARWR recovered 2.69 points in tracked return to -1.01%, with the latest quote at $89.59 up 4.16% on 0.91x participation. The rising EMA structure and 4.43-point sector-relative advantage support a repair attempt aligned with the published efficacy report, but neutral flow, RSI 74.93 and no current VWAP capture leave the recovery unconfirmed.

ARWR improved 1.26 points since the previous note to a -3.70% tracked return; the latest capture is $86.99, up 1.14%, but still 0.11% below VWAP on 0.11x participation. Its rising EMA structure and modest sector outperformance make this a repair attempt, yet RSI 72.96 and the absence of stronger demand leave the recovery unconfirmed.

ARWR remains at a -4.96% tracked return on day 9, with the latest quote at $86.01, up 1.61% on only 0.57x volume. Price is holding above a rising EMA structure, but weak participation and RSI 71.93 make this a repair attempt rather than evidence of durable demand.

ARWR added 0.54 points from the last note to -5.50%; the latest capture is $86.01, up 1.61% on 0.57x volume. Price remains above a rising EMA structure, but weak participation and high RSI mean the efficacy-linked thesis is repairing rather than demonstrating durable demand.

ARWR improved 0.65 percentage points to -5.50% on day 8, while the current session is up 0.75% on 0.40x relative volume. Price remains above the rising EMA structure, but weak participation means the efficacy-linked thesis is still repairing rather than confirmed.

ARWR recovered 0.31 points to -6.15% on day 8, while the current session adds 0.24% on only 0.12x relative volume. Price above VWAP and a rising EMA structure suggest repair, but weak participation and RSI 70.88 do not yet confirm renewed demand.

ARWR remains at -6.46% on day 8 while the current session loses 3.06% on 0.75x relative volume. Rising EMA support and RSI at 65.97 have not stopped the retreat; the efficacy-linked thesis remains in repair rather than confirming renewed demand.

ARWR remains at -6.46% on day 7, while the current session is down 3.06% on 0.75x relative volume. The rising EMA structure still offers support and RSI is 65.97, but continued loss of ground keeps the efficacy-linked thesis in repair rather than confirming renewed demand.

ARWR has slipped to -6.46% on day 7 after the latest public update gave back 0.73 percentage points; current price is $84.65 with -3.06% session change and 0.75x relative volume. The rising EMA structure still offers support, but the continued loss of ground keeps the efficacy-linked thesis in repair rather than confirming renewed demand.

ARWR has slipped to -6.46% on day 7 after the latest public update gave back 0.73 percentage points; current price is $84.65 with -3.06% session change and 0.75x relative volume. The rising EMA structure still offers support, but the continued loss of ground keeps the efficacy-linked thesis in repair rather than confirming renewed demand.

ARWR has slipped to -5.73% on day 7 after a 2.21% session decline, while relative volume fell to 0.46x and the rising EMA structure still offers some support. The earlier recovery has given back ground without a structural break, so the public catalyst thesis remains a repair case rather than confirmed renewed demand.

ARWR has slipped to -5.73% on day 7 after a 2.21% session decline, while relative volume fell to 0.46x and the rising EMA structure still offers some support. The earlier recovery has given back ground without a structural break, so the public catalyst thesis remains a repair case rather than confirmed renewed demand.

ARWR has eased to -4.95% on day 7 after a -0.97% session move, with 0.14x relative volume even as the EMA structure remains upward. The earlier repair has not carried into stronger demand, so the efficacy-linked thesis remains under pressure rather than re-established.

ARWR has eased to -4.95% on day 7 after a -0.97% session move, with 0.14x relative volume even as the EMA structure remains upward. The earlier repair has not carried into stronger demand, so the efficacy-linked thesis remains under pressure rather than re-established.

ARWR recovered to -3.51% on day 7 with a 1.28% session gain, but participation remains light at 0.62x relative volume. The constructive structure offers some repair without fully restoring the thesis, so the next check is stronger participation accompanying further recovery.

ARWR recovered to -3.51% on day 7 with a 1.28% session gain, but participation remains light at 0.62x relative volume. The constructive structure offers some repair without fully restoring the thesis, so the next check is stronger participation accompanying further recovery.

ARWR recovered 0.45 percentage points from the last public update but remains at -3.51% in tracking. The constructive EMA structure and positive session are not yet matched by strong participation, so the recovery thesis remains under pressure; the next check is stronger participation accompanying further recovery.

ARWR recovered 0.45 percentage points from the last public update but remains at -3.51% in tracking. The constructive EMA structure and positive session are not yet matched by strong participation, so the recovery thesis remains under pressure; the next check is stronger participation accompanying further recovery.

ARWR gave back 0.68 percentage points since the last public update and now stands at -3.96% in tracking. The recovery thesis remains under pressure despite the prior rebound; the next check is stronger participation accompanying any further recovery.

ARWR gave back 0.68 percentage points since the last public update and now stands at -3.96% in tracking. The recovery thesis remains under pressure despite the prior rebound; the next check is stronger participation accompanying any further recovery.

ARWR has recovered 1.45 percentage points since the last public update but remains at -3.28% in tracking. The recovery thesis is still under pressure; stronger participation is the next observable confirmation.

ARWR has recovered 1.45 percentage points since the last public update but remains at -3.28% in tracking. The recovery thesis is still under pressure; stronger participation is the next observable confirmation.

ARWR remains at -4.73% in tracking, with no additional return change since the last public update. The recovery thesis remains under pressure, and stronger participation is still the next observable confirmation.

ARWR remains at -4.73% in tracking, with no additional return change since the last public update. The recovery thesis remains under pressure, and stronger participation is still the next observable confirmation.

ARWR is now at -4.73% in tracking, a -0.49 percentage-point change versus the last public update. The next check is whether this move holds with continued participation while the published thesis remains conditional.

ARWR is now at -4.73% in tracking, a -0.49 percentage-point change versus the last public update. The next check is whether this move holds with continued participation while the published thesis remains conditional.

ARWR recovered 0.98 percentage points to a prepared return of -4.24% since the previous public update. The recovery thesis remains under pressure, and stronger participation is the next observable confirmation.

ARWR recovered 0.98 percentage points to a prepared return of -4.24% since the previous public update. The recovery thesis remains under pressure, and stronger participation is the next observable confirmation.

ARWR is unchanged at a prepared return of -5.22%, with price above VWAP but only 0.61x time-adjusted relative volume. The recovery thesis remains under pressure; stronger participation is the next observable confirmation.

ARWR is unchanged at a prepared return of -5.22%, with price above VWAP but only 0.61x time-adjusted relative volume. The recovery thesis remains under pressure; stronger participation is the next observable confirmation.

ARWR recovered 0.97 percentage points to a prepared return of -5.22%, with price above VWAP but only 0.61x time-adjusted relative volume. No fresh issuer event is available, so the thesis remains under pressure until stronger participation confirms the recovery.

ARWR recovered 0.97 percentage points to a prepared return of -5.22%, with price above VWAP but only 0.61x time-adjusted relative volume. No fresh issuer event is available, so the thesis remains under pressure until stronger participation confirms the recovery.

ARWR recovered 0.97 percentage points to a prepared return of -6.19%, with price above VWAP but only 0.61x time-adjusted relative volume. No fresh issuer event is available, so the thesis remains under pressure until stronger participation confirms the recovery.

ARWR recovered 0.97 percentage points to a prepared return of -6.19%, with price above VWAP but only 0.61x time-adjusted relative volume. No fresh issuer event is available, so the thesis remains under pressure until stronger participation confirms the recovery.

ARWR remains under pressure in the prepared update. No fresh issuer event is available, and a sustained return above VWAP with stronger participation is still the missing confirmation.

ARWR remains under pressure in the prepared update. No fresh issuer event is available, and a sustained return above VWAP with stronger participation is still the missing confirmation.

ARWR slipped from -4.06% to -5.49%, moving from $86.83 to $85.53. The thesis remains under pressure: no fresh issuer event is available, and a sustained return above VWAP with stronger participation is still the missing confirmation.

ARWR slipped from -4.06% to -5.49%, moving from $86.83 to $85.53. The thesis remains under pressure: no fresh issuer event is available, and a sustained return above VWAP with stronger participation is still the missing confirmation.

ARWR slipped from -5.41% to -5.49%, with price nearly unchanged at $85.53 versus $85.60 in the previous public note. The thesis remains under pressure: there is no fresh issuer event in the prepared evidence, and a return above VWAP with stronger participation is still the missing confirmation.

ARWR slipped from -5.41% to -5.49%, with price nearly unchanged at $85.53 versus $85.60 in the previous public note. The thesis remains under pressure: there is no fresh issuer event in the prepared evidence, and a return above VWAP with stronger participation is still the missing confirmation.

ARWR is now -4.06%, a 1.35-point recovery from the prior -5.41% note, with the latest public price at $86.83 versus $85.60. The thesis remains under pressure despite the repair; a sustained return above VWAP with stronger participation is still the missing confirmation, and no fresh issuer event is available.

ARWR is now -4.06%, a 1.35-point recovery from the prior -5.41% note, with the latest public price at $86.83 versus $85.60. The thesis remains under pressure despite the repair; a sustained return above VWAP with stronger participation is still the missing confirmation, and no fresh issuer event is available.

ARWR is -5.41%, a further 0.34-point deterioration from the prior -5.07% note, with the latest price at $85.60 and no fresh issuer event in the prepared evidence. The thesis remains under pressure; a return above VWAP with stronger participation is still the missing confirmation.

ARWR is -5.41%, a further 0.34-point deterioration from the prior -5.07% note, with the latest price at $85.60 and no fresh issuer event in the prepared evidence. The thesis remains under pressure; a return above VWAP with stronger participation is still the missing confirmation.

ARWR is -5.41%, a further 0.34-point deterioration from the prior -5.07% note, with the latest price at $85.60 and no fresh issuer event in the prepared evidence. The thesis remains under pressure; a return above VWAP with stronger participation is still the missing confirmation.

ARWR is -5.41%, a further 0.34-point deterioration from the prior -5.07% note, with the latest price at $85.60 and no fresh issuer event in the prepared evidence. The thesis remains under pressure; a return above VWAP with stronger participation is still the missing confirmation.

ARWR moved from -2.90% to -5.07%, a 2.17-point deterioration since the previous public note. The regular-session tape remains below VWAP with range position at 0.304 and decelerating 0.61 time RVOL; no fresh issuer event is present, so the published thesis stays under pressure without a new explanation.

ARWR moved from -2.90% to -5.07%, a 2.17-point deterioration since the previous public note. The regular-session tape remains below VWAP with range position at 0.304 and decelerating 0.61 time RVOL; no fresh issuer event is present, so the published thesis stays under pressure without a new explanation.

ARWR slipped 0.91 points to -2.90% from the previous public note, while remaining above VWAP with a 0.626 range position and 1.18 relative volume. No issuer-specific event appeared, so the modest move does not change the published reading.

ARWR slipped 0.91 points to -2.90% from the previous public note, while remaining above VWAP with a 0.626 range position and 1.18 relative volume. No issuer-specific event appeared, so the modest move does not change the published reading.

ARWR is -1.99% from its reference after the session advanced with a confirmed public efficacy report and 3.32x observed volume. That evidence keeps the original momentum case in view, but follow-through still needs to hold after the headline before the initial move can be treated as durable.

ARWR is -1.99% from its reference after the session advanced with a confirmed public efficacy report and 3.32x observed volume. That evidence keeps the original momentum case in view, but follow-through still needs to hold after the headline before the initial move can be treated as durable.